BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Diabetes mellitus
,
Endothelial cell
,
Amniocentesis
,
Vitamin E
,
rs7903146
,
ZBTB7A
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
peptides i
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Colorectal cancer HT29 cells treated with ligand perturbagens
L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
L1000 CMAP - Embryonic kidney epithelial HA1E cells treated with ligand perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
Virtual screening and characteristics of novel umami peptides from porcine type I collagen.
Inner residues of macrothiolactone in autoinducer peptides I/IV circumvent spontaneous S-to-O acyl t…
Highly Efficient Cyclization Approach of Propargylated Peptides via Gold(I)-Mediated Sequential C-N,…
Export of diverse and bioactive peptides through a type I secretion system.
Changes in RACK1 expression induce defects in nodulation and development in Phaseolus vulgaris.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Phase I In-Vivo Peptide Applied in the Right Colon
A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas
A Phase I Study to Evaluate LSALT Peptide
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-…
ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ